TipRanks
Go Ultimate55% OFF
PC:HEMOS

HemostOD: Valuation, Funding & Investors

HemostOD is a Swiss preclinical-stage healthcare company focused on developing a scalable and universal source of platelets produced ex vivo. Utilizing its proprietary bioreactor technology, HemostOD creates platelets in vitro from immortalized hematopoietic stem cells, eliminating the need for donors. This innovation aims to improve safety and availability, potentially transforming transfusion medicine by addressing the recurring shortages of platelets in medical care.

Leadership & Board

Latest Estimated Valuation

Total Amount Raised
$4M
Total Funding Rounds
1
Latest Funding Amount
$4M
Latest Funding Round
Seed Round

Funding Round

Funding DateFunding RoundAmount RaisedPost-Money Valuation
Oct 08, 2025Seed Round$4.30M―

Investors

Investor NameFunding Round
Polytech VenturesSeed Round
Orenok HoldingsSeed Round
Lichtsteiner FoundationSeed Round

Similar Companies

A snapshot of private companies similar to HemostOD, helping you discover and navigate related company profiles.

Related News and Analysis